NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
2-[4-(trifluoromethyl)phenyl]-5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-ol
|
|
|
IUPAC Traditional name
|
2-[4-(trifluoromethyl)phenyl]-5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-ol
|
|
|
Synonyms
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
12.525094
|
H Acceptors
|
3
|
H Donor
|
1
|
LogD (pH = 5.5)
|
4.43885
|
LogD (pH = 7.4)
|
4.4388576
|
Log P
|
4.438861
|
Molar Refractivity
|
86.678 cm3
|
Polarizability
|
28.26515 Å3
|
Polar Surface Area
|
46.01 Å2
|
Rotatable Bonds
|
2
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Selleck Chemicals
Selleck Chemicals -
S1180
|
Research Area
|
Description
|
Cancer |
Biological Activity
|
Description
|
XAV-939 is a selective Wnt β-catenin-mediated transcription inhibitor for TNKS1 and TNKS2 with IC50 of 11 nM and 4 nM, respectively. |
Targets
|
TNKS1 |
TNKS2 |
|
|
|
|
IC50 |
11 nM |
4 nM [1] |
|
|
|
|
In Vitro
|
XAV-939 specifically inhibits tankyrase PARP activity. XAV-939 dramatically decreases DNA-PKcs protein levels, confirming the critical role of tankyrase poly-ADP-ribosylation activity in maintaining stability of the DNA-PKcs protein. The greatest reduction of DNA-PKcs protein levels (< 25%="" relative="" expression="" compared="" to="" dmso="" treated="" controls)="" occurs="" at="" 12="" hours="" with="" 1.0="" μm="" xav-939="" exposure.="" treatment="" of="" human="" lymphoblasts="" with="" 1.0="" μm="" xav-939="" results="" in="" marked="" elevation="" of="" tankyrase="" 1="" levels.="">[1] XAV-939 is axin stabilizing agent. XAV-939 stimulates beta-catenin degradation by stabilizing axin, the concentration-limiting component of the destruction complex. XAV-939 stabilizes axin by blocking the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. XAV-939 deregulates the Wnt/b-catenin pathway which has been implicated in many cancers. [2] |
In Vivo
|
|
Clinical Trials
|
|
Features
|
|
Protocol
|
Cell Assay
[1]
|
Cell Lines |
WTK1 lymphoblasts |
Concentrations |
1.0 μM |
Incubation Time |
8 hours |
Methods |
XAV-939 is solubilized in DMSO at 55 °C to make a 10 mM stock solution which may be diluted later to a working concentration of 100 μM. WTK1 lymphoblasts treated with either DMSO or 1.0 μM XAV-939 for 8 hours are loaded into independent wells of a 4-20% gradient SDS-PAGE every 2 hours over the course of 6 hours. At each time point, DMSO and XAV-939 samples are loaded into wells immediately adjacent to the prior time point. The corresponding load times at 0, 2 and 4 hours results in total run times of 2, 4 and 6 hours respectively. The gel is analyzed via western blot for DNA-PKcs following completion of the final run time and is quantified after normalization to actin loading controls. |
|
PATENTS
PATENTS
PubChem Patent
Google Patent